Rosiglitazone can reduce the level of arachidonic acid, similar to the level of ACSL4 knockout cells, and also improve the survival rate of Gpx4 knockout mice to avoid renal failure death (Doll et al., 2017). Here, ACSL4 is linked to kidney failure.